Sanofi's SAR446523 gains FDA orphan drug status, offering hope for relapsed multiple myeloma patients with its targeted ...

SAR446523, an investigational antibody targeting GPRC5D, received FDA orphan drug status and is in phase 1 trials for ...

FDA granted Orphan Drug Designation to Sanofi’s SAR446523, a monoclonal antibody targeting GPRC5D, for relapsed/refractory ...

Sanofi’s SAR446523, a GPRC5D monoclonal antibody, earns orphan drug designation in the US for multiple myeloma Designation granted for IgG1-based GPRC5D monoclonal antibody for the potential treatment ...

G protein-coupled receptor, class C, group 5, member D (GPRC5D) loss after chimeric antigen receptor (CAR) T-cell therapy in ...

LBL-034 is an investigational GPRC5D-targeted CD3 bispecific antibody. The Food and Drug Administration (FDA) has granted Orphan Drug designation to LBL-034 for the treatment of multiple myeloma.

Beyond this patient, we identified that relapses after GPRC5D-directed CAR T-cell therapy were associated with decreased or no expression of GPRC5D messenger RNA (mRNA) (Figure 1F and Fig. S2 and ...

DelveInsight's GPRC5D-directed Therapies Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding of current treatment practices ...

These results provide support that GPRC5D is a new and effective target for the immunotherapy of myeloma, consistent with the results reported for talquetamab, a bispecific T-cell engager ...

Sanofi’s SAR446523, a GPRC5D monoclonal antibody, earns orphan drug designation in the US for multiple myeloma Designation granted for IgG1-based GPRC5D monoclonal antibody for the potential treatment ...